FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Glick

Research Profile

Chemicals & Drugs

Disorders

Activities & Behaviors

Drug Evaluation

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Eli Glatstein; John Glick; Larry Kaiser; Stephen M Hahn
Should randomized clinical trials be required for proton radiotherapy? An alternative view.
Angela DeMichele; Richard Aplenc; Jeffrey Botbyl; Theresa Colligan; Lisa Wray; Melissa Klein-Cabral; Andrea Foulkes; Phyllis A Gimotty; John Glick; Barbara Weber; Edward A Stadtmauer; Timothy R Rebbeck
Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.
Karen Smith; Lisa Wray; Melissa Klein-Cabral; Lynn Schuchter; Kevin Fox; John Glick; Angela DeMichele
Ethnic disparities in adjuvant chemotherapy for breast cancer are not caused by excess toxicity in black patients.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Glick (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Eli Glatstein; John Glick; Larry Kaiser; Stephen M Hahn
Should randomized clinical trials be required for proton radiotherapy? An alternative view.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(15):2438-9.
2005: Angela DeMichele; Richard Aplenc; Jeffrey Botbyl; Theresa Colligan; Lisa Wray; Melissa Klein-Cabral; Andrea Foulkes; Phyllis A Gimotty; John Glick; Barbara Weber; Edward A Stadtmauer; Timothy R Rebbeck
Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(24):5552-9.
2005: Karen Smith; Lisa Wray; Melissa Klein-Cabral; Lynn Schuchter; Kevin Fox; John Glick; Angela DeMichele
Ethnic disparities in adjuvant chemotherapy for breast cancer are not caused by excess toxicity in black patients.
Clinical breast cancer 2005;6(3):260-6; discussion 267-9.
2004: Roberto J Santiago; Leester Wu; Eleanor Harris; Kevin Fox; Delray Schultz; John Glick; Lawrence J Solin
Fifteen-year results of breast-conserving surgery and definitive irradiation for Stage I and II breast carcinoma: the University of Pennsylvania experience.
International journal of radiation oncology, biology, physics 2004;58(1):233-40.
2003: Angela DeMichele; Mary E Putt; Yawei Zhang; John Glick; Sandra A Norman
Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients.
Cancer 2003;97(9):2150-9.
2003: Eleanor E R Harris; Delray Schultz; Helaine Bertsch; Kevin Fox; John Glick; Lawrence J Solin
Ten-year outcome after combined modality therapy for inflammatory breast cancer.
International journal of radiation oncology, biology, physics 2003;55(5):1200-8.
2003: Constance M Yuan; Steven Stein; John Glick; Mariusz A Wasik
Natural killer-like T-cell lymphoma of the small intestine with a distinct immunophenotype and lack of association with gluten-sensitive enteropathy.
Archives of pathology & laboratory medicine 2003;127(3):e142-6.
2003: David B Duggan; Gina R Petroni; Jeffrey L Johnson; John Glick; Richard I Fisher; Joseph Michael Connors; George P Canellos; Bruce A Peterson
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):607-14.
2001: J H Chang; E Vines; Helaine Bertsch; Douglas L Fraker; Brian J Czerniecki; Ernest F Rosato; Thomas Lawton; Emily F Conant; Susan G Orel; Lynn Schuchter; Kevin R Fox; N Zieber; John Glick; Lawrence J Solin
The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience.
Cancer 2001;91(7):1231-7.
2000: James M Metz; Delray J Schultz; K Fox; A Mathews; John Glick; Lawrence J Solin
Analysis of outcomes for high-risk breast cancer based on interval from surgery to postmastectomy radiation therapy.
Cancer journal (Sudbury, Mass.) 2000;6(5):324-30.
1999: James M Metz; Delray J Schultz; K Fox; John Glick; Lawrence J Solin
Long-term outcome after postmastectomy radiation therapy for breast cancer patients at high risk for local-regional recurrence.
The cancer journal from Scientific American 1999;5(2):77-83.
1998: DA Markiewicz; K R Fox; Delray J Schultz; Eleanor E R Harris; J A Haas; John Glick; Lawrence J Solin
Concurrent chemotherapy and radiation for breast conservation treatment of early-stage breast cancer.
The cancer journal from Scientific American 1998;4(3):185-93.
1998: John Glick; M L Young; D Harrington; R L Schilsky; T Beck; R Neiman; Richard I Fisher; Bruce A Peterson; Martin M Oken
MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(1):19-26.
1996: John Glick
American Society of Clinical Oncology: a society in transition.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(8):2388-98.
1996: D A Markiewicz; Delray J Schultz; J A Haas; Eleanor E R Harris; K R Fox; John Glick; Lawrence J Solin
The effects of sequence and type of chemotherapy and radiation therapy on cosmesis and complications after breast conservation therapy.
International journal of radiation oncology, biology, physics 1996;35(4):661-8.
1994: BL Fowble; Delray J Schultz; Beth Overmoyer; Lawrence J Solin; K Fox; L Jardines; Susan G Orel; John Glick
The influence of young age on outcome in early stage breast cancer.
International journal of radiation oncology, biology, physics 1994;30(1):23-33.
1988: John Glick; B L Fowble; D G Haller; E F Rosato; J A Mackie; C Weiler; D J Glover; K R Fox; S Hurwitz; R L Goodman
Integration of full-dose adjuvant chemotherapy with definitive radiotherapy for primary breast cancer: four-year update.
NCI monographs : a publication of the National Cancer Institute 1988;(6):297-301.
1988: D Glover; K R Fox; C Weiler; M M Kligerman; Andrew Turrisi; John Glick
Clinical trials of WR-2721 prior to alkylating agent chemotherapy and radiotherapy.
Pharmacology & therapeutics 1988;39(1-3):3-7.
1988: L M Shaw; D Glover; Andrew Turrisi; D Q Brown; Heather S Bonner; A L Norfleet; C Weiler; John Glick; M M Kligerman
Pharmacokinetics of WR-2721.
Pharmacology & therapeutics 1988;39(1-3):195-201.
1987: D J Glover; John Glick
Metabolic oncologic emergencies.
CA: a cancer journal for clinicians 1987;37(5):302-20.
1987: D Glover; John Glick; C Weiler; K Fox; D Guerry
WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(4):574-8.
1986: D Glover; John Glick; C Weiler; K Fox; Andrew Turrisi; M M Kligerman
Phase I/II trials of WR-2721 and cis-platinum.
International journal of radiation oncology, biology, physics 1986;12(8):1509-12.
1986: D Glover; John Glick; C Weiler; S Hurowitz; M M Kligerman
WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(4):584-8.
1985: D J Glover; L Shaw; John Glick; E Slatopolsky; C Weiler; M Attie; S Goldfarb
Treatment of hypercalcemia in parathyroid cancer with WR-2721, S-2-(3-aminopropylamino)ethyl-phosphorothioic acid.
Annals of internal medicine 1985;103(1):55-7.
1984: D Glover; John Glick; C Weiler; J Yuhas; M M Kligerman
Phase I trials of WR-2721 and cis-platinum.
International journal of radiation oncology, biology, physics 1984;10(9):1781-4.
1984: John Glick; D Glover; C Weiler; L Norfleet; J Yuhas; M M Kligerman
Phase I controlled trials of WR-2721 and cyclophosphamide.
International journal of radiation oncology, biology, physics 1984;10(9):1777-80.
1984: M M Kligerman; D J Glover; Andrew Turrisi; A L Norfleet; J M Yuhas; L R Coia; C Simone; John Glick; R L Goodman
Toxicity of WR-2721 administered in single and multiple doses.
International journal of radiation oncology, biology, physics 1984;10(9):1773-6.
1982: John Glick; D J Glover; C Weiler; A Blumberg; D Nelson; J M Yuhas; M Kligerman
Phase I clinical trials of WR-2721 with alkylating agent chemotherapy.
International journal of radiation oncology, biology, physics 1982;8(3-4):575-80.
1982: D J Glover; J M Yuhas; John Glick
WR-2721: enhanced chemoprotection by increasing cyclophosphamide activation with phenobarbitol.
International journal of radiation oncology, biology, physics 1982;8(3-4):571-4.
1982: A L Blumberg; D F Nelson; M Gramkowski; D Glover; John Glick; J M Yuhas; M M Kligerman
Clinical trials of WR-2721 with radiation therapy.
International journal of radiation oncology, biology, physics 1982;8(3-4):561-3.
1981: M M Kligerman; A L Blumberg; John Glick; D F Nelson; D Glover; J M Yuhas; Howard Amols; R L Goodman
Phase I trials of WR2721 in combination with radiation therapy and with the alkylating agents cyclophosphamide and cis-platinum.
Cancer clinical trials 1981;4(4):469-74.